Jubilant Ingrevia: Prabhudas Lilladher Recommends 'Hold' with Rs 657 Target

• Jubilant Ingrevia reported consolidated revenue of Rs 10.5 billion, meeting estimates.
• Chemical Intermediate segment de-grew by 14% QoQ and 2% YoY due to pricing pressure.
• Nutrition & Health Solution segment grew 11% QoQ and 6% YoY, driven by Vitamin B3 volume.
• Specialty segment saw improved pharma demand but weak Agrochemicals due to pyridine price softening.
• Prabhudas Lilladher maintains a 'Hold' rating with a target price of Rs 657, citing pricing headwinds in some segments.